📊 GCAN Key Takeaways
Is GCAN a Good Investment? Thesis Analysis
Greater Cannabis Company exhibits catastrophic financial deterioration with revenue collapsing 73.7% YoY to just $12.6K while losses widened to -$669.4K, resulting in a negative stockholders' equity position of -$1.1M. The company is operationally insolvent with liabilities exceeding assets by $1.08M, negative gross margins, and severely negative cash flow generation, indicating imminent solvency crisis.
Why Buy GCAN? Key Strengths
- Minimal long-term debt burden limits future refinancing risks
- No recent insider selling activity in last 90 days suggests insiders have already exited
- Data is current as of Q3 2025, providing recent visibility
GCAN Investment Risks to Consider
- Negative stockholders' equity of -$1.1M indicates technical insolvency and shareholder value destruction
- Revenue collapse of 73.7% YoY with minimal absolute revenue ($12.6K) suggests business model failure or operational shutdown
- Current ratio of 0.02x indicates company cannot cover current liabilities with current assets; imminent liquidity crisis
- Operating cash outflow of -$36K against near-zero revenue demonstrates unsustainable business operations
- Negative gross margin indicates pricing below cost structure; core business fundamentally unprofitable
Key Metrics to Watch
- Total stockholders' equity trajectory toward further negative territory or potential delisting
- Monthly revenue trend to confirm whether business is dissolving or stabilizing
- Cash burn rate and remaining runway before complete depletion of $21.4K cash position
GCAN Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
GCAN Profitability Ratios
GCAN vs Healthcare Sector
How Greater Cannabis Company, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GCAN Overvalued or Undervalued?
Based on fundamental analysis, Greater Cannabis Company, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GCAN Balance Sheet & Liquidity
GCAN 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Greater Cannabis Company, Inc.'s revenue has declined by 87% over the 5-year period, indicating business contraction. The most recent EPS of $0.00 indicates the company is currently unprofitable.
GCAN Growth Metrics (YoY)
GCAN Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2022 | $12.6K | -$39.0K | $0.00 |
| Q2 2022 | $12.6K | -$39.0K | $0.00 |
| Q3 2021 | $12.6K | -$39.0K | N/A |
| Q2 2021 | $12.6K | -$39.0K | N/A |
| Q3 2020 | $2.6K | -$126.4K | N/A |
| Q2 2020 | $48.0K | -$109.1K | N/A |
| Q3 2019 | $2.3K | $22.3K | N/A |
| Q2 2019 | $22.5K | $22.3K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GCAN Capital Allocation
GCAN SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Greater Cannabis Company, Inc. (CIK: 0001695473)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GCAN
What is the AI rating for GCAN?
Greater Cannabis Company, Inc. (GCAN) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are GCAN's key strengths?
Claude: Minimal long-term debt burden limits future refinancing risks. No recent insider selling activity in last 90 days suggests insiders have already exited.
What are the risks of investing in GCAN?
Claude: Negative stockholders' equity of -$1.1M indicates technical insolvency and shareholder value destruction. Revenue collapse of 73.7% YoY with minimal absolute revenue ($12.6K) suggests business model failure or operational shutdown.
What is GCAN's revenue and growth?
Greater Cannabis Company, Inc. reported revenue of $12.6K.
Does GCAN pay dividends?
Greater Cannabis Company, Inc. does not currently pay dividends.
Where can I find GCAN SEC filings?
Official SEC filings for Greater Cannabis Company, Inc. (CIK: 0001695473) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GCAN's EPS?
Greater Cannabis Company, Inc. has a diluted EPS of $-0.85.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GCAN a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Greater Cannabis Company, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GCAN stock overvalued or undervalued?
Valuation metrics for GCAN: ROE of N/A (sector avg: 15%), net margin of -5,299.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GCAN stock in 2026?
Our dual AI analysis gives Greater Cannabis Company, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GCAN's free cash flow?
Greater Cannabis Company, Inc.'s operating cash flow is $-36.0K, with capital expenditures of N/A. FCF margin is -285.1%.
How does GCAN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5,299.8% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.02 (avg: 2).